Entera Bio Ltd. (NASDAQ:ENTX)
| Market Cap | 121.75M+15.7% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -17.03M-60.7% |
| EPS | -0.35-251.6% |
| Shares Out | 49.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,282.876 |
| Open | 2.48 |
| Previous Close | 2.51 |
| Day's Range | 2.47 - 2.48 |
| 52-Week Range | 0.91 - 4.20 |
| Beta | 1.41 |
| Analysts | Buy |
| Price Target | 9.00(+264.37%) |
| Earnings Date | Nov 13, 2026 |
Insiders here have filed 7 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ENTX
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ENTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ENTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ENTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ENTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ENTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ENTX from public contracts
Source: USAspending.gov
ENTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ENTX’s recent data — informational, not investment advice